Posted by Michael Wonder on 31 Dec 2019
MorphoSys announces submission of biologics license application for tafasitamab in r/r DLBCL to the FDA
30 December 2019 - MorphoSys announced today that it has submitted a biologics license application to the U.S. FDA for tafasitamab, an anti-CD19 antibody, for the treatment of relapsed or refractory diffuse large B cell lymphoma.
The submission is based on the primary analysis data from the L-MIND trial of tafasitamab in combination with lenalidomide in patients with relapsed or refractory (r/r) diffuse large B lymphoma (DLBCL) and the retrospective observational matched control cohort Re-MIND evaluating efficacy outcomes of r/r DLBCL patients who received lenalidomide monotherapy.
